TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07508787: A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant

Sponsor: Nefro Avillion Clinical Development, LLC · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 120 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,826,000

Rescue Site Savings

+$1,195,200

Unlock Full NCT07508787 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07508787 Rescue Dossier →